Results 111 to 120 of about 158,302 (232)

Is amnioinfusion for intrapartum variable decelerations effective? Evaluation of the total deceleration area: A retrospective cohort study

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective Data regarding the efficiency of amnioinfusion in the presence of recurrent variable decelerations (VD) are limited. Total deceleration area (TDA) has been shown to be a useful indicator of both intrapartum fetal acid–base status and neonatal morbidity.
Gal Cohen, Nofar Bar Noy‐Traub, Hanoch Schreiber, Tal Biron‐Shental, Hila Shalev‐Ram, Michal Kovo, Dorit Ravid   +6 more
wiley   +1 more source

Steps toward clinical validation of exhaled volatile organic compound biomarkers for hypoglycemia in persons with type 1 diabetes. [PDF]

Sci Rep
Woollam M, Angarita-Rivera P, Thakur S, Daneshkhah A, Siegel AP, Hardin DS, Agarwal M.   +6 more
europepmc   +1 more source

Antenatal dexamethasone for late preterm delivery: Rate of complete course and neonatal outcomes

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This retrospective cohort study aimed to assess the rate of complete dexamethasone administration among late preterm deliveries and its impact on neonatal outcomes. Methods We reviewed medical records of 1500 late preterm deliveries (gestational age 34–36 + 6 weeks) between January 2018 and December 2020, analyzing baseline ...
Piyamon Srisakulpanich, Pattarawalai Talungchit, Tachjaree Panchalee, Chutima Yaiyiam   +3 more
wiley   +1 more source

Hypoglycemia associated with fluoroquinolone: a pharmacovigilance analysis from 2014 to 2023 based on the FDA adverse event reporting system. [PDF]

Front Med (Lausanne)
Li D, Zhang Y, Wang YQ, Cheng L, Zhou XD, Chen J, Feng GW, Chen YL, Chen Y, Xuan ZX, Chen L.   +10 more
europepmc   +1 more source

Alterations and mechanistic insights of gut microbiota and its metabolites in type 2 diabetes mellitus and Alzheimer's disease

iMetaOmics, EarlyView.
This narrative review uniquely addresses how gut microbiota‐derived metabolites mediate overlapping pathologies of insulin resistance, neuroinflammation, and amyloidogenesis in type 2 diabetes mellitus (T2DM) and Alzheimer's disease (AD), proposing a framework for dual therapeutic targeting.
Guangyi Xu, Yu An, Yage Du, Zhaoming Cao, Jie Zheng, Jingya Wang, Tingyi Li, Xingen Lei, Yanhui Lu   +8 more
wiley   +1 more source

Patient Experiences and Treatment Satisfaction with Mini-Dose Glucagon as a Treatment for Hypoglycemia Following Repeated, Prolonged Fasts in Type 1 Diabetes During Ramadan. [PDF]

J Clin Med
Algeffari M, Hussain S, Alsharidah M, Alkhalifah S, Almogbel T.   +4 more
europepmc   +1 more source

Temporal response patterns of human gut microbiota to dietary fiber

iMeta, EarlyView.
In this study, 19 overweight participants, with or without type 2 diabetes mellitus, underwent 14 days of normal‐diet observation followed by 14 days of dietary fiber intervention. Fecal samples and continuous glucose monitoring data were collected daily throughout the 28‐day period.
Xiaotong Lin, Chaoxun Wang, Biao Liu, Yin Zhu, Rui Zhai, Chenhong Zhang   +5 more
wiley   +1 more source

Recurrent education: A promising strategy for enhancing diabetes management and reducing hypoglycemia in children with type 1 diabetes. [PDF]

BMC Endocr Disord
Güneş Kaya D, Bayramoğlu E, Turan H, Karaca E, Eyüpoğlu GZ, Pirdal BZ, Evliyaoğlu SO.   +6 more
europepmc   +1 more source

Effects of Hepatic or Renal Impairment on Pharmacokinetics of Fruquintinib

The Journal of Clinical Pharmacology, EarlyView.
Abstract Fruquintinib (FRUZAQLATM) is a highly selective tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors (‐1, ‐2, and ‐3). Two Phase 1, open‐label, single‐dose studies investigated the impact of hepatic or renal impairment on the pharmacokinetics and tolerability of fruquintinib.
Martha Gonzalez, Zhao Yang, William Schelman, Thomas C. Marbury, Juan C. Rondon, William Smith, Xiaofei Zhou, Neeraj Gupta, Caly Chien   +8 more
wiley   +1 more source

Medically Refractory Nesidioblastosis as a Late Adverse Effect of Roux-en-Y Gastric Bypass. [PDF]

Cureus
Ladna M.
europepmc   +1 more source